DeHeng Assisted YRPG in RMB 800 Million Strategic Investment in Recbio

2025-10-21

Recently, DeHeng assisted Yangtze River Pharmaceutical Group Co., Ltd. (“YRPG”) in completing a strategic investment in the innovative vaccine company Jiangsu Recbio Technology Co., Ltd. (“Recbio,” 02179.HK).

During this investment process, DeHeng lawyers participated in various tasks, including legal due diligence on Recbio, investment plan analysis, verification of investor information, validation of subscriber eligibility, and the drafting, review, and revision of investment documents such as the Private Placement Share Subscription Agreement.

As the legal counsel for the investor YRPG in this project, the DeHeng team, led by partner Dai Xiang from its Shanghai Office, with primary support from lawyers Li Chaoran, Hu Chenghao, and Wang Jiaqing, and trainee lawyer Zhao Ruqiang, provided specialized legal services for this transaction.